Peter W. Letebdre
Keine laufenden Positionen mehr
Profil
Peter W.
Letendre joined Replidyne, Inc. in March 2005 as Chief Commercial Officer.
He held various commercial positions at SmithKline Beecham, GlaxoSmithKline and Abbott Laboratories.
Dr. Letendre was Vice President and General Manager of the Anti-Infective Franchise for Abbott Laboratories.
He was Marketing Director of Diabetes Franchise for SmithKline Beecham and GlaxoSmithKline from 2000 to 2002 and Marketing Director of Augmentin® and Timentin from 2000 to 2002.
Dr. Letendre was Product Manager and Senior Product Manager of Paxil, Requip and Bactroban and an Associate Dean of Clinical Practice at Southeastern University of the Health Sciences.
He received a BS degree and a Doctor of Pharmacy degree from the Massachusetts College of Pharmacy and Allied Health Sciences.
Ehemalige bekannte Positionen von Peter W. Letebdre
| Unternehmen | Position | Ende |
|---|---|---|
Replidyne, Inc.
 Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Corporate Officer/Principal | - |
Ausbildung von Peter W. Letebdre
| Massachusetts College of Pharmacy & Health Science | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
